Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 20/20 | 0.75 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.60 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.60 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.60 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 17/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | BMX | P51813 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.60 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16993011 | 0.90 | FGFR1 (0.74) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL18522397 | 0.89 | FGFR1 (0.75) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993003 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993313 | 0.85 | FGFR1 (0.80) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993159 | 0.84 | FGFR1 (0.74) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Trifluoroacetic Acid SCHEMBL29545726 | 0.83 | FGFR1 (0.70) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993004 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16260610 | 0.81 | FGFR1 (0.63) | FGFR1FGFR2 | |
| SCHEMBL18522569 | 0.81 | FGFR1 (0.79) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL19499709 | 0.80 | FGFR1 (0.59) | FGFR1FGFR2CSF1RLYNFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-08-01 | — | — | US | disclosed |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-3102577-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3102577-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 202/4885FGFR3 2/4885 |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885CSF1R 104/4885FGFR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.